PCRX - Pacira BioSciences Inc Stock Price, Fair Value and News

29.99USD+3.48 (+13.13%)Delayed as of 08 May 2024, 02:01 pm ET

Market Summary

USD29.99+3.48

Delayedas of 08 May 2024, 02:01 pm

13.13%

PCRX Alerts

Big jump in Earnings (Y/Y)

PCRX Stock Price

View Fullscreen

PCRX RSI Chart

PCRX Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

17.51

Price/Sales (Trailing)

1.81

EV/EBITDA

7.62

Price/Free Cashflow

7.12

PCRX Price/Sales (Trailing)

PCRX Profitability

Operating Margin

73.15%

EBT Margin

14.93%

Return on Equity

7.9%

Return on Assets

4.45%

Free Cashflow Yield

14.04%

PCRX Fundamentals

PCRX Revenue

Revenue (TTM)

681.8M

Rev. Growth (Yr)

4.23%

Rev. Growth (Qtr)

-7.79%

PCRX Earnings

Earnings (TTM)

70.5M

Earnings Growth (Yr)

145.96%

Earnings Growth (Qtr)

-63.9%

Breaking Down PCRX Revenue

52 Week Range

28.3843.50

(Low)(High)

Last 7 days

1.0%

Last 30 days

-5.9%

Last 90 days

-7.0%

Trailing 12 Months

-37.3%

How does PCRX drawdown profile look like?

PCRX Financial Health

Current Ratio

5.81

Debt/Equity

0.45

Debt/Cashflow

0.46

PCRX Investor Care

Shares Dilution (1Y)

1.21%

Diluted EPS (TTM)

1.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	681.8M	0	0	0
2023	669.2M	669.2M	665.7M	675.0M
2022	580.5M	614.3M	654.1M	666.8M
2021	443.0M	503.1M	513.3M	541.5M
2020	435.4M	408.3M	421.1M	429.6M
2019	354.0M	372.5M	393.7M	421.0M
2018	292.0M	305.1M	321.2M	337.3M
2017	280.2M	281.5M	280.5M	286.6M
2016	256.2M	266.6M	272.8M	276.4M
2015	355.2M	367.2M	377.3M	249.0M
2014	110.6M	140.7M	169.4M	333.5M
2013	42.9M	47.7M	62.4M	85.6M
2012	19.6M	28.3M	32.9M	39.1M
2011	13.6M	14.2M	13.6M	15.7M
2010	14.9M	14.8M	14.7M	14.6M
2009	0	0	0	15.0M
2008	0	0	0	13.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Pacira BioSciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 08, 2024	pace gary w	sold	-2,754,000	30.6	-90,000	-
Mar 07, 2024	pace gary w	sold	-870,598	30.81	-28,257	-
Mar 06, 2024	pace gary w	sold	-31,628	29.67	-1,066	-
Feb 05, 2024	williams kristen	acquired	-	-	33,700	chief administrative officer
Feb 05, 2024	gaugler daryl	acquired	-	-	33,700	chief operating officer
Jan 02, 2024	riker lauren	sold (taxes)	-5,088	32.00	-159	senior vice president, finance
Jan 02, 2024	slonin jonathan	acquired	-	-	5,000	chief medical officer
Jan 02, 2024	lee frank d.	acquired	-	-	99,520	chief executive officer
Aug 02, 2023	winston roy	sold	-17,751	34.875	-509	chief medical officer
Jul 05, 2023	riker lauren bullaro	sold	-25,019	38.91	-643	senior vice president, finance

Which funds bought or sold PCRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Leisure Capital Management	sold off	-100	-11,151	-	-%
May 06, 2024	Spectrum Wealth Counsel, LLC	unchanged	-	-2,712	17,532	-%
May 06, 2024	Quantbot Technologies LP	reduced	-32.31	-100,895	142,944	0.01%
May 06, 2024	Jefferies Financial Group Inc.	added	82.8	1,074,370	2,137,800	0.01%
May 06, 2024	HighTower Advisors, LLC	added	64.97	128,000	424,000	-%
May 06, 2024	DUALITY ADVISERS, LP	added	1.77	-136,811	1,016,390	0.10%
May 06, 2024	Retirement Planning Co of New England, Inc.	sold off	-100	-211,887	-	-%
May 06, 2024	Van Hulzen Asset Management, LLC	added	1.32	-140,000	1,005,000	0.07%
May 06, 2024	Parallel Advisors, LLC	reduced	-20.36	-2,931	6,516	-%
May 06, 2024	NEW YORK LIFE INVESTMENT MANAGEMENT LLC	added	46.68	77,754	365,455	-%

Are Funds Buying or Selling PCRX?

Are funds buying PCRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PCRX

No. of Funds

PCRX Alerts

Big jump in Earnings (Y/Y)

Unveiling Pacira BioSciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	10.98%	5,098,424	SC 13G/A
Jan 19, 2024	blackrock inc.	17.5%	8,113,714	SC 13G/A
Feb 14, 2023	macquarie group ltd	4.44%	2,037,049	SC 13G/A
Feb 09, 2023	vanguard group inc	10.73%	4,925,195	SC 13G/A
Jan 23, 2023	blackrock inc.	15.8%	7,250,908	SC 13G/A
Mar 02, 2022	baillie gifford & co	4.84%	2,170,707	SC 13G/A
Feb 14, 2022	macquarie group ltd	9.44%	4,205,522	SC 13G/A
Jan 27, 2022	blackrock inc.	15.3%	6,821,518	SC 13G/A
Jan 27, 2022	baillie gifford & co	5.29%	2,355,240	SC 13G
Jan 26, 2022	blackrock inc.	15.3%	6,821,518	SC 13G/A

Recent SEC filings of Pacira BioSciences Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
Apr 22, 2024	DEFA14A	DEFA14A
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	ARS	ARS
Mar 08, 2024	4	Insider Trading
Mar 06, 2024	144	Notice of Insider Sale Intent
Feb 29, 2024	S-8	Employee Benefits Plan
Feb 29, 2024	8-K	Current Report
Feb 29, 2024	10-K	Annual Report

Peers (Alternatives to Pacira BioSciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.6B	-2.43%	-8.39%	9.3	4.18	5.68%	202.39%
MRK	330.2B	61.4B	1.86%	10.13%	143.19	5.38	6.11%	-82.30%
AMGN	161.1B	29.5B	11.28%	28.04%	42.82	5.46	12.76%	-52.47%
PFE	156.8B	46.5B	4.16%	-28.19%	-112.94	3.37	42.59%	-114.62%
GILD	81.5B	27.1B	-5.96%	-16.75%	14.39	3.01	-0.60%	23.36%
TEVA	15.6B	15.8B	-2.04%	54.08%	-27.14	0.99	6.17%	76.47%
MID-CAP
ALKS	4.2B	1.7B	-5.86%	-20.45%	9.58	2.41	54.01%	364.56%
PRGO	4.1B	4.6B	-3.95%	-16.22%	-533.77	0.9	-0.06%	94.55%
BHC	2.7B	9.0B	-28.82%	23.71%	-5.97	0.3	10.01%	-27.45%
AMPH	2.1B	644.4M	2.42%	17.52%	14.96	3.19	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-23.46%	-28.42%	-4.38	2.07	24.65%	80.36%
TXMD	23.2M	1.3M	-9.05%	-48.20%	-2.26	17.8	-98.14%	-109.18%
ACRX	17.0M	-	-15.25%	35.14%	-0.92	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	31.03%	-94.02%	-0.19	0.14	80.00%	43.08%
ACOR	1.1M	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Pacira BioSciences Inc News

Latest updates

Pacira BioSciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-7.8%	167	181	164	169	160	172	167	169	158	159	128	136	119	131	117	76.00	106	122	105	103	91.00
Cost Of Revenue	-0.6%	47.00	48.00	40.00	48.00	49.00	62.00	51.00	51.00	36.00	39.00	35.00	35.00	31.00	35.00	30.00	22.00	30.00	32.00	22.00	25.00	27.00
Costs and Expenses	3.9%	154	148	146	130	163	182	146	138	141	155	96.00	101	100	112	100	83.00	89.00	121	102	97.00	90.00
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	121	102	97.00	90.00
S&GA Expenses	9.5%	72.00	66.00	68.00	65.00	71.00	64.00	61.00	65.00	64.00	52.00	48.00	51.00	49.00	53.00	53.00	43.00	45.00	54.00	50.00	49.00	47.00
R&D Expenses	-6.3%	18.00	19.00	21.00	19.00	17.00	18.00	19.00	26.00	22.00	16.00	12.00	13.00	16.00	15.00	15.00	14.00	16.00	20.00	20.00	18.00	14.00
EBITDA Margin	19.5%	0.28*	0.23*	0.19*	0.18*	0.16*	0.22*	0.21*	0.23*	0.22*	0.22*	0.24*	0.21*	-	-	-	-	-	-	-	-	-
Interest Expenses	-2.1%	3.00	3.00	3.00	4.00	10.00	11.00	10.00	9.00	10.00	10.00	7.00	7.00	7.00	7.00	7.00	5.00	6.00	6.00	6.00	6.00	6.00
Income Taxes	-47.3%	5.00	9.00	6.00	12.00	-6.94	-7.97	3.00	2.00	0.00	-1.07	7.00	7.00	2.00	-1.82	-123	-0.04	0.00	1.00	0.00	-1.60	0.00
Earnings Before Taxes	-59.5%	14.00	34.00	17.00	38.00	-26.47	-18.07	2.00	22.00	7.00	-6.20	24.00	26.00	13.00	13.00	6.00	-7.31	9.00	-3.54	-5.82	1.00	-2.52
EBT Margin	63.4%	0.15*	0.09*	0.01*	-0.01*	-0.03*	0.02*	0.04*	0.08*	0.09*	0.10*	0.15*	0.11*	-	-	-	-	-	-	-	-	-
Net Income	-63.9%	9.00	25.00	11.00	26.00	-19.54	-10.10	-0.69	20.00	7.00	-5.13	18.00	19.00	10.00	15.00	130	-7.27	8.00	-4.89	-6.09	3.00	-2.77
Net Income Margin	66.3%	0.10*	0.06*	0.01*	-0.01*	-0.02*	0.02*	0.03*	0.06*	0.07*	0.08*	0.12*	0.35*	-	-	-	-	-	-	-	-	-
Free Cashflow	1.0%	46.00	46.00	41.00	40.00	13.00	37.00	37.00	18.00	23.00	14.00	47.00	20.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	0.6%	1,583	1,574	1,534	1,542	1,523	1,681	1,734	1,734	1,891	2,075	1,356	1,326	1,288	1,275	1,220	866	821	831	807	788	719
Current Assets	6.5%	543	510	447	429	376	498	533	526	667	866	822	793	720	652	659	456	432	409	379	395	509
Cash Equivalents	20.1%	184	153	99.00	87.00	36.00	104	109	122	227	586	134	106	67.00	100	125	79.00	55.00	78.00	85.00	60.00	215
Inventory	-7.3%	97.00	104	97.00	92.00	93.00	96.00	97.00	101	104	99.00	67.00	65.00	65.00	65.00	69.00	67.00	60.00	58.00	60.00	53.00	47.00
Net PPE	-1.2%	172	174	176	180	182	184	194	191	190	188	159	153	145	137	126	113	108	105	105	105	107
Goodwill	0.0%	163	163	163	163	163	163	157	146	146	145	100	100	100	100	100	100	100	100	100	101	38.00
Liabilities	-1.9%	691	704	703	734	755	906	964	977	1,182	1,345	637	639	637	655	636	478	447	476	461	446	392
Current Liabilities	-4.0%	93.00	97.00	94.00	109	99.00	148	132	133	305	521	226	229	232	253	86.00	71.00	80.00	108	96.00	83.00	59.00
Long Term Debt	0.2%	399	399	398	397	405	405	404	404	403	339	326	322	317	313	456	314	310	306	302	298	294
LT Debt, Current	0%	9.00	9.00	9.00	9.00	-	-	-	-	160	350	156	154	152	150	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	399	398	397	405	405	404	404	403	339	326	322	317	313	456	314	310	306	302	298	294
Shareholder's Equity	2.5%	892	870	832	808	768	775	770	757	710	730	719	687	651	620	585	388	374	355	346	342	328
Retained Earnings	8.4%	-97.82	-106	-131	-142	-168	-148	-138	-137	-157	-211	-206	-224	-243	-253	-268	-398	-391	-399	-394	-388	-391
Additional Paid-In Capital	1.3%	990	977	963	951	936	924	909	895	868	942	925	911	894	873	852	785	766	754	740	730	718
Shares Outstanding	0.1%	47.00	46.00	46.00	46.00	46.00	46.00	45.00	45.00	45.00	44.00	44.00	44.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,300	-	-	-	1,900	-	-	-	1,600	-	-	-	1,600	-	-	-	848	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	3.2%	49,101	47,584	44,438	43,499	19,128	42,037	42,654	29,806	30,777	23,215	60,287	30,134	12,081	46,667	39,781	-15,624	6,208	25,904	18,354	22,763	3,499
Share Based Compensation	5.9%	13,151	12,420	12,530	10,955	11,990	12,677	12,682	11,544	11,189	10,891	10,784	10,461	10,110	10,897	10,954	9,222	8,847	9,189	9,244	7,783	7,434
Cashflow From Investing	-285.5%	-15,530	8,374	-4,342	7,326	66,183	11,189	-47,516	19,161	-208,019	66,918	-35,077	3,033	-55,664	-82,317	-202,847	36,123	-28,566	-30,795	5,625	-181,799	78,481
Cashflow From Financing	-58.3%	-2,817	-1,779	-27,787	440	-153,905	-58,511	-7,775	-153,657	-181,585	361,409	3,052	5,908	10,325	10,363	209,758	3,464	-1,281	-2,020	1,423	3,737	530

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PCRX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 674,978	$ 666,823	$ 541,533
Operating expenses:
Cost of goods sold	184,669	199,295	140,255
Research and development	76,257	84,797	55,545
Selling, general and administrative	269,441	254,516	199,345
Amortization of acquired intangible assets	57,288	57,288	13,553
Contingent consideration (gains) charges, acquisition-related charges and other	(352)	10,903	42,911
Total operating expenses	587,303	606,799	451,609
Income from operations	87,675	60,024	89,924
Other (expense) income:
Interest income	11,444	4,542	896
Interest expense	(20,306)	(39,976)	(31,750)
Loss on early extinguishment of debt	(16,926)	0	0
Other, net	(186)	(11,288)	(2,666)
Total other expense, net	(25,974)	(46,722)	(33,520)
Income before income taxes	61,701	13,302	56,404
Income tax (expense) benefit	(19,746)	2,607	(14,424)
Net income	$ 41,955	$ 15,909	$ 41,980
Net income per share:
Basic net income per common share (in dollars per share)	$ 0.91	$ 0.35	$ 0.95
Diluted net income per common share (in dollars per share)	$ 0.89	$ 0.34	$ 0.92
Weighted average common shares outstanding:
Basic (in shares)	46,222	45,521	44,262
Diluted (in shares)	51,979	46,538	45,630
Net product sales
Revenues:
Total revenues	$ 672,245	$ 664,150	$ 538,966
Royalty revenue
Revenues:
Total revenues	2,733	2,673	2,442
Collaborative licensing and milestone revenue
Revenues:
Total revenues	$ 0	$ 0	$ 125

PCRX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 153,298	$ 104,139
Short-term available-for-sale investments	125,283	184,512
Accounts receivable, net	105,556	98,397
Inventories, net	104,353	96,063
Prepaid expenses and other current assets	21,504	15,223
Total current assets	509,994	498,334
Noncurrent available-for-sale investments	2,410	37,209
Fixed assets, net	173,927	183,512
Right-of-use assets, net	61,020	70,877
Goodwill	163,243	163,243
Intangible assets, net	483,258	540,546
Deferred tax assets	144,485	160,309
Investments and other assets	36,049	27,170
Total assets	1,574,386	1,681,200
Current liabilities:
Accounts payable	15,698	15,220
Accrued expenses	64,243	89,785
Lease liabilities	8,801	9,121
Current portion of convertible senior notes, net	8,641	0
Current portion of long-term debt, net	0	33,648
Total current liabilities	97,383	147,774
Convertible senior notes, net	398,594	404,767
Long-term debt, net	115,202	251,056
Lease liabilities	54,806	64,802
Contingent consideration	24,698	28,122
Other liabilities	13,573	9,669
Total liabilities	704,256	906,190
Commitments and contingencies (Note 20)
Stockholders’ equity:
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, par value $0.001; 250,000,000 shares authorized; 46,481,174 and 45,927,790 shares issued and outstanding at December 31, 2023 and 2022, respectively	46	46
Additional paid-in capital	976,633	924,095
Accumulated deficit	(106,796)	(148,751)
Accumulated other comprehensive income (loss)	247	(380)
Total stockholders’ equity	870,130	775,010
Total liabilities and stockholders’ equity	$ 1,574,386	$ 1,681,200

About Pacira BioSciences Inc

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

CEO	Mr. David M. Stack
WEBSITE	pacira.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	715

Pacira BioSciences Inc Frequently Asked Questions

What is the ticker symbol for Pacira BioSciences Inc? What does PCRX stand for in stocks?

PCRX is the stock ticker symbol of Pacira BioSciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pacira BioSciences Inc (PCRX)?

As of Tue May 07 2024, market cap of Pacira BioSciences Inc is 1.23 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PCRX stock?

You can check PCRX's fair value in chart for subscribers.

What is the fair value of PCRX stock?

You can check PCRX's fair value in chart for subscribers. The fair value of Pacira BioSciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pacira BioSciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PCRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pacira BioSciences Inc a good stock to buy?

The fair value guage provides a quick view whether PCRX is over valued or under valued. Whether Pacira BioSciences Inc is cheap or expensive depends on the assumptions which impact Pacira BioSciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PCRX.

What is Pacira BioSciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, PCRX's PE ratio (Price to Earnings) is 17.51 and Price to Sales (PS) ratio is 1.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PCRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pacira BioSciences Inc's stock?

In the past 10 years, Pacira BioSciences Inc has provided -0.097 (multiply by 100 for percentage) rate of return.